(NASDAQ: PMVP) Pmv Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Pmv Pharmaceuticals's earnings in 2026 is -$78,344,000.On average, 6 Wall Street analysts forecast PMVP's earnings for 2026 to be -$79,602,994, with the lowest PMVP earnings forecast at -$80,488,301, and the highest PMVP earnings forecast at -$76,157,762. On average, 5 Wall Street analysts forecast PMVP's earnings for 2027 to be -$60,744,881, with the lowest PMVP earnings forecast at -$62,195,506, and the highest PMVP earnings forecast at -$56,558,338.
In 2028, PMVP is forecast to generate -$52,766,449 in earnings, with the lowest earnings forecast at -$50,697,177 and the highest earnings forecast at -$54,318,404.